Oncolytics Biotech Inc (ONC)

Toronto
Currency in CAD
1.11
+0.01(+0.91%)
Closed

ONC Income Statement

Advanced Income Statement
Period Ending:
2014
31/12
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Total Revenues Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Cost Of Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Gross Profit Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Gross Profit Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Other Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa20.1425.4626.2426.9233.79
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa+16.62%+26.39%+3.05%+2.63%+25.51%
aa.aaaa.aaaa.aaaa.aaaa.aa10.8212.9512.9215.4317.71
aa.aaaa.aaaa.aaaa.aaaa.aa9.3312.5113.3211.4916.08
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-20.14-25.46-26.24-26.92-33.79
Operating Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-16.62%-26.39%-3.05%-2.63%-25.51%
EBIT Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Interest Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa0.180.120.10.531.33
Net Interest Expenses Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+3.33%-32.51%-18.18%+433.33%+151.14%
Interest Expense, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Interest And Investment Income
aa.aaaa.aaaa.aaaa.aaaa.aa0.180.120.10.531.33
Other Non Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-0.322.83-0.121.654.81
EBT, Excl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-20.28-22.51-26.26-24.75-27.66
Gain (Loss) On Sale Of Assets
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Other Unusual Items, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-12.61----
EBT, Incl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-33.12-22.51-26.26-24.75-27.66
EBT, Incl. Unusual Items Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-100.88%+32.06%-16.66%+5.73%-11.73%
EBT, Incl. Unusual Items Margin
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Income Tax Expense
aa.aaaa.aaaa.aaaa.aaaa.aa--0.050.080.1
Net Income to Company
aa.aaaa.aaaa.aaaa.aaaa.aa-33.12-22.51-26.3-24.84-27.75
Minority Interest
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-33.12-22.51-26.3-24.84-27.75
Net Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-94.41%+32.06%-16.88%+5.58%-11.75%
Net Income Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Preferred Dividend and Other Adjustments
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income to Common Excl. Extra Items
aa.aaaa.aaaa.aaaa.aaaa.aa-33.12-22.51-26.3-24.84-27.75
Basic EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-1.5-0.56-0.49-0.43-0.41
Basic EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-40.66%+62.71%+11.89%+12.93%+4.11%
Diluted EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-1.5-0.56-0.49-0.43-0.41
Diluted EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-40.66%+62.71%+11.89%+12.93%+4.11%
Basic Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa22.1440.3453.5158.0367.62
Diluted Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa22.1440.3453.5158.0367.62
Dividend Per Share
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Dividend Per Share Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-----
EBITDA
aa.aaaa.aaaa.aaaa.aa